文献速递心境障碍

双相障碍中长效针剂与口服抗精神病药的比较

Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder.
PubMed 文献 · Am J Psychiatry · 2026-09-09

该研究基于香港电子健康记录,采用自身对照病例系列设计,纳入同时接受长效针剂和口服抗精神病药的双相障碍患者,比较两种治疗期间医疗利用、复发及安全性。结果显示长效针剂与全因急诊、全因住院、精神科住院及躁狂和混合发作住院风险降低相关,抑郁发作住院、非精神科住院及心血管住院无显著差异,初期锥体外系症状风险增加但90天后不显著。

要点

  • 长效针剂与口服药相比,全因急诊、全因住院、精神科住院、躁狂及混合发作住院风险显著降低。
  • 抑郁发作住院、非精神科住院及心血管住院风险在两种治疗间无显著差异。
  • 长效针剂初期锥体外系症状风险增加,但治疗超过90天后差异不显著。

核心结论

  • 长效针剂与双相障碍患者医疗利用减少及躁狂和混合发作复发减少相关,且不增加非精神科住院(尤其心血管疾病)风险。
  • 研究结果支持在双相障碍中使用长效针剂,但起始阶段需密切监测锥体外系症状。

研究设计与样本

  • 共纳入17,841名双相障碍患者,其中2,086名(11.7%)同时接受长效针剂和口服抗精神病药处方。
  • 采用条件泊松回归估计长效针剂与口服抗精神病药治疗期间调整发病率比(aIRR)。

主要发现

  • 长效针剂与口服药相比,全因急诊就诊风险显著降低(aIRR=0.85,95% CI=0.81, 0.89)。
  • 长效针剂与全因住院风险显著降低相关(aIRR=0.79,95% CI=0.73, 0.85)。
  • 长效针剂与精神科住院风险显著降低相关(aIRR=0.67,95% CI=0.61, 0.74)。
  • 长效针剂与躁狂发作住院风险显著降低相关(aIRR=0.51,95% CI=0.44, 0.59),与混合发作住院风险显著降低相关(aIRR=0.31,95% CI=0.14, 0.66)。
  • 抑郁发作住院(aIRR=1.34,95% CI=0.94, 1.93)、非精神科住院(aIRR=0.97,95% CI=0.87, 1.08)及心血管住院(aIRR=0.84,95% CI=0.62, 1.14)风险无统计学显著差异。

临床怎么用

  • 对于双相障碍患者,可考虑使用长效针剂以减少医疗利用及躁狂和混合发作复发。
  • 长效针剂起始阶段应密切监测锥体外系症状。
  • 长效针剂不增加非精神科住院及心血管住院风险,但抑郁发作住院风险需关注。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Long-acting injectable antipsychotics (LAIAs) can improve adherence, but their optimal use in bipolar disorder needs to be further explored. This study compared LAIAs and oral antipsychotics with respect to health care utilization, illness relapse, and safety in individuals with bipolar disorder. METHODS: A self-controlled case series study was conducted using data from Hong Kong's electronic health records on individuals with bipolar disorder who received prescriptions for both LAIAs and oral antipsychotics during the period of January 1, 2004, through December 31, 2023. Outcomes included measures of health care utilization, illness relapse, and safety. Adjusted incidence rate ratios (aIRRs) for LAIA versus oral antipsychotic treatment periods were estimated using conditional Poisson regression. RESULTS: Among 17,841 people with bipolar disorder, 2,086 (11.7%) received prescriptions for both LAIAs and oral antipsychotics. Compared with oral antipsychotics, LAIAs were associated with statistically significantly lower risks of all-cause emergency department visits (aIRR=0.85, 95% CI=0.81, 0.89), all-cause hospitalizations (aIRR=0.79, 95% CI=0.73, 0.85), psychiatric hospitalizations (aIRR=0.67, 95% CI=0.61, 0.74), hospitalizations for manic episodes (aIRR=0.51, 95% CI=0.44, 0.59), and hospitalizations for mixed episodes (aIRR=0.31, 95% CI=0.14, 0.66). No statistically significant difference was found for hospitalizations for depressive episodes (aIRR=1.34, 95% CI=0.94, 1.93), nonpsychiatric hospitalizations (aIRR=0.97, 95% CI=0.87, 1.08), or cardiovascular hospitalizations (aIRR=0.84, 95% CI=0.62, 1.14). LAIAs were initially associated with an increased risk of extrapyramidal symptoms (aIRR=2.95, 95% CI=1.40, 6.22), but this difference was not statistically significant beyond 90 days of treatment. CONCLUSIONS: LAIAs were associated with substantially less health care utilization and fewer relapses of manic and mixed episodes, and they were not associated with increased risk of nonpsychiatric hospitalizations, notably for cardiovascular disease. These findings support the use of LAIAs for bipolar disorder, with close monitoring for extrapyramidal symptoms during initiation.

来源:Am J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Deng EK, Huang C, Yan VKC, et al. Comparison of Long-Acting Injectable and Oral Antipsychotics in Bipolar Disorder. Am J Psychiatry. 2026. PMID: 42711749. doi:10.1176/appi.ajp.20250793

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。